{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"82.8","upperLimit":"91.2","value":"87"},{"groupId":"OG001","lowerLimit":"80","upperLimit":"89.3","value":"84.7"}]}],"title":"At 3 years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"66","upperLimit":"79.7","value":"72.9"},{"groupId":"OG001","lowerLimit":"61.1","upperLimit":"76","value":"68.5"}]}],"title":"At 5 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"261"},{"groupId":"OG001","value":"257"}],"units":"Participants"}],"description":"Defined as the percentage of patients still alive and followed at 3 and 5 years post beginning of treatment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Palbociclib 125 mg daily and AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt)","id":"OG000","title":"Arm A"},{"description":"AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant)","id":"OG001","title":"Arm B"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"5 years","title":"3 and 5 Year Survival Probabilities","type":"SECONDARY","unitOfMeasure":"percentage of patients alive"}